SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Rosano, GMC; Tamargo, J; Kjeldsen, KP; Lainscak, M; Agewall, S; Anker, SD; Ceconi, C; Coats, AJS; Drexel, H; Filippatos, G; et al. Rosano, GMC; Tamargo, J; Kjeldsen, KP; Lainscak, M; Agewall, S; Anker, SD; Ceconi, C; Coats, AJS; Drexel, H; Filippatos, G; Kaski, JC; Lund, L; Niessner, A; Savarese, G; Schmidt, TA; Seferovic, P; Wassmann, S; Walther, T; Lewis, BS (2018) Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother, 4 (3). pp. 180-188. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvy015
SGUL Authors: Kaski, Juan Carlos

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (954kB) | Preview

Abstract

Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard end-points. RAASi are also the basis in treatment of arterial hypertension and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. RAASi therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their therapy down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level.

Item Type: Article
Additional Information: This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following peer review. The version of record Giuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, Mitja Lainscak, Stefan Agewall, Stefan D Anker, Claudio Ceconi, Andrew J S Coats, Heinz Drexel, Gerasimos Filippatos, Juan Carlos Kaski, Lars Lund, Alexander Niessner, Gianluigi Savarese, Thomas A Schmidt, Petar Seferovic, Sven Wassmann, Thomas Walther, Basil S Lewis; Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology, European Heart Journal - Cardiovascular Pharmacotherapy, , pvy015, is available online at: https://doi.org/10.1093/ehjcvp/pvy015
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J Cardiovasc Pharmacother
ISSN: 2055-6845
Language: eng
Dates:
DateEvent
1 July 2018Published
3 May 2018Published Online
26 April 2018Accepted
Publisher License: Publisher's own licence
PubMed ID: 29726985
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109814
Publisher's version: https://doi.org/10.1093/ehjcvp/pvy015

Actions (login required)

Edit Item Edit Item